Launch AYVAKIT in advanced SM in the U.S

Deadline passed; outcome being checked

What the company said

“launch AYVAKIT in advanced SM in the U.S. in the second half of 2021”

SourceBlueprint Medicines Corp Form 8-K press release, 2021-01-11
FilingSEC filing index
Deadline as statedin the second half of 2021
Deadline used31 Dec 2021, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-C597264-021764
Cite as https://keptindex.org/c/KI-C-2021-C597264-021764/ — this address never changes.

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Version 1 · original · stated 11 Jan 2021

Deadline 31 Dec 2021 (“in the second half of 2021”)
Version 2 · stated 17 Feb 2021

Deadline 30 Jun 2021 (“in the first half of 2021”)

“launch AYVAKIT in advanced SM in the U.S. in the first half of 2021.”
Source for this version

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Blueprint Medicines Corp? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.